A study led by IBEC and ISGlobal has demonstrated the antileishmanial potential of an antimalarial compound. Initially designed for malaria, this drug shows high efficacy against leishmaniasis, representing a unique and promising breakthrough for the treatment of both infections.
Delivering effector molecules in cells in vitro and ex vivo by photoporation. Kevin Braeckmans, Biophotonics Research Group, Lab. General Biochemistry and Physical Pharmacy, Ghent University, Belgium Delivery of bioactive compounds, … Read more
Experts in nanomedicine from various fields have gathered today for the fifth consecutive year at Nano Rare Diseases Day. This event is co-organized by the NANOMED Spain platform, coordinated by IBEC, and SJD Barcelona Children’s Hospital, showcasing the latest advances in nanomedicine for the diagnosis and treatment of rare diseases.
Ref: PR_PR // Deadline: 13/03/2024
I usually use videos as containers for different materials, that´s why I am collecting texts, images and videos from my environment. I will create my visual material mainly via Ibec, … Read more
Ref: PD_MOB_SS // Deadline: 17/03/2024
Ref: PhD_XR//Deadline: 22/03/2024
Molecular and mechanical regulation of abscission in stem cells Agathe Chaigne, PhD., Group leader. Cell Biology, Neurobiology and Biophysics department, Utrecht University, The Netherlands Abscission is the last step of … Read more
From February 14 to 16, IBEC hosted 20 research managers from Widening countries. This initiative, promoted by the NCP_WIDERA.NET project, aims for these managers to acquire the best practices of centers of excellence to apply them in their own institutions and explore possible synergies.